ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Syntrix Completes Initial SX-682 Dosing in Cancer Trial Campaign americanpharmaceuticalreview
November 05, 2020Syntrix Pharmaceuticals has completed initial SX-682 dosing in Phase 1/2 trials in myelodysplastic syndromes (MDS) and metastatic melanoma. The drug was well tolerated and absorbed with excellent dose-proportional drug levels in blood.
Pharma Sources Insight January 2025
